AI Article Synopsis
- Researchers outlined safe transportation conditions for freshly harvested human bone marrow-derived mesenchymal stem cells (hBM-MSC) using human platelet lysate (hPL), ensuring they can be used quickly as a therapeutic product.
- The study emphasizes key factors to consider when comparing various transportation methods, noting that while cell viability may decrease during transport, it doesn't significantly affect the cells' ability to promote bone regeneration.
- Overall, the findings suggest that despite potential viability loss, cGMP-compliant hBM-MSC can still maintain effective regenerative properties post-transportation.
Article Abstract
We recently described conditions for safe 18-h manufacturer-to-patient transportation of freshly harvested hBM-MSC expanded under cGMP protocols using human platelet lysate (hPL), that allowed prompt use as an advanced therapeutic medicinal product. Here we outline important considerations when comparing different transportation conditions, highlighting that although cell transportation may involve a reduction in viability, this did not undermine the ultimate bone-forming regenerative potential of the cGMP-hBM-MSC population.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/7651_2014_105 | DOI Listing |
Publication Analysis
Top Keywords
transportation conditions
8
cgmp-compliant transportation
4
conditions prompt
4
prompt therapeutic
4
therapeutic marrow
4
marrow mesenchymal
4
mesenchymal stromal/stem
4
stromal/stem cells
4
cells described
4
described conditions
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!